Radiation to control transgene expression in tumors

Cancer Biology and Therapy

Volumn 6, Issue 7, 2007, Pages 1005-1012

  Marignol, Laure ^a,b   Coffey, M ^b   Hollywood, D ^a   Lawler, M ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Gene therapy; Hypoxia; Radiation

Indexed keywords

CRE RECOMBINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; EARLY GROWTH RESPONSE FACTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45 ALPHA; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

BINDING SITE; CANCER CONTROL; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CLOSTRIDIUM; CYTOTOXICITY; GENE CONTROL; GENE EXPRESSION; HUMAN; HYPOXIA; NONHUMAN; PROMOTER REGION; REVIEW; SUICIDE GENE; TREATMENT RESPONSE; TUMOR GENE;

EID: 42449136598     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.7.4477     Document Type: Review

References (98)

1. Chastel C, Jiricny J, Jaussi R. Activation of stress-responsive promoters by ionizing radiation for deployment in targeted gene therapy. DNA Repair (Amst) 2004; 3:201-15.
2. Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP, Kufe DW. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994; 54:4266-9.
3. Hallahan DE, Sukhatme VP, Sherman ML, Virudachalam S, Kufe D, Weichselbaum RR. Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci USA 1991; 88:2156-60.
4. Hamdi M, Kool J, Cornelissen-Steijger P, Carlotti F, Popeijus HE, van der Burgt C, Janssen JM, Yasui A, Hoeben RC, Terleth C, Mullenders LH, van Dam H. DNA damage in transcribed genes induces apoptosis via the JNK pathway and the JNK-phosphatase MKP-1. Oncogene 2005; 24:7135-44.
5. Beetz A, Peter RU, Oppel T, Kaffenberger W, Rupec RA, Meyer M, van Beuningen D, Kind P, Messer G. NF-kappaB and AP-1 are responsible for inducibility of the IL-6 promoter by ionizing radiation in HeLa cells. Int J Radiat Biol 2000; 76:1443-53.
6. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13:1109-66.
7. Martin M, Vozenin MC, Gault N, Crechet F, Pfarr CM, Lefaix JL. Coactivation of AP-1 activity and TGF-beta1 gene expression in the stress response of normal skin cells to ionizing radiation. Oncogene 1997; 15:981-9.
8. Witte L, Fuks Z, Haimovitz-Friedman A, Vlodavsky I, Goodman DS, Eldor A. Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells. Cancer Res 1989; 49:5066-72.
9. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371:534-7.
10. Flores-Rozas H, Kelman Z, Dean FB, Pan ZQ, Harper JW, Elledge SJ, O'Donnell M, Hurwitz J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci USA 1994; 91:8655-9.
11. Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, El-Deiry WS. p53-dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab 2005; 90:3568-74.
12. Fornace Jr AJ, Alamo Jr I, Hollander MC. DNA damage-inducible transcripts in mammalian cells. Proc Natl Acad Sci USA 1988; 85:8800-4.
13. Fornace Jr AJ, Nebert DW, Hollander MC, Luethy JD, Papathanasiou M, Fargnoli J, Holbrook NJ. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 1989; 9:4196-203.
14. Papathanasiou MA, Kerr NC, Robbins JH, McBride OW, Alamo Jr I, Barrett SF, Hickson ID, Fornace Jr AJ. Induction by ionizing radiation of the gadd45 gene in cultured human cells: Lack of mediation by protein kinase C. Mol Cell Biol 1991; 11:1009-16.
15. Jin S, Fan F, Fan W, Zhao H, Tong T, Blanck P, Alomo I, Rajasekaran B, Zhan Q. Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. Oncogene 2001; 20:2683-90.
16. Lefort K, Rouault JP, Tondereau L, Magaud JP, Dore JF. The specific activation of gadd45 following UVB radiation requires the POU family gene product N-oct3 in human melanoma cells. Oncogene 2001; 20:7375-85.
17. Takahashi S, Saito S, Ohtani N, Sakai T. Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Res 2001; 61:1187-95.
18. Daino K, Ichimura S, Nenoi M. Comprehensive search for X-ray-responsive elements and binding factors in the regulatory region of the GADD45a gene. J Radiat Res (Tokyo) 2003; 44:311-8.
19. Miskin R, Reich E. Plasminogen activator: Induction of synthesis by DNA damage. Cell 1980; 19:217-24.
20. Boothman DA, Lee IW, Sahijdak WM. Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: Potential uses of X-ray-responsive elements for gene therapy. Radiat Res 1994; 138:S68-71.
21. Fujiwara J, Kimura T, Ayusawa D, Oishi M. A novel regulatory sequence affecting the constitutive expression of tissue plasminogen activator (tPA) gene in human melanoma (Bowes) cells. J Biol Chem 1994; 269:18558-62.
22. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343:774-8.
23. Datta R, Rubin E, Sukhatme V, Qureshi S, Hallahan D, Weichselbaum RR, Kufe DW. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 1992; 89:10149-53.
24. Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, Kufe DW. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA 1993; 90:2419-22.
25. Hsu H, Rainov NG, Quinones A, Eling DJ, Sakamoto KM, Spear MA. Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter. Anticancer Res 2003; 23:2723-8.
26. Christy B, Nathans D. Functional serum response elements upstream of the growth factor-inducible gene zif268. Mol Cell Biol 1989; 9:4889-95.
27. Treisman R. The SRE: A growth factor responsive transcriptional regulator. Semin Cancer Biol 1990; 1:47-58.
28. Tsai-Morris CH, Cao XM, Sukhatme VP. 5′ flanking sequence and genomic structure of Egr-1, a murine mitogen inducible zinc finger encoding gene. Nucleic Acids Res 1988; 16:8835-46.
29. Meyer RG, Kupper JH, Kandolf R, Rodemann HP. Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro. Eur J Biochem 2002; 269:337-46.
30. Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther 2000; 7:1126-31.
31. Nenoi M, Daino K, Ichimura S, Takahash S, Akuta T. Low-dose radiation response of the p21WAF1/CIP1 gene promoter transduced by adeno-associated virus vector. Exp Mol Med 2006; 38:553-64.
32. Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther 1995; 6:1507-13.
33. Anton M, Gomaa IE, von Lukowicz T, Molls M, Gansbacher B, Wurschmidt F. Optimization of radiation controlled gene expression by adenoviral vectors in vitro. Cancer Gene Ther 2005; 12:640-6.
34. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 2000; 7:511-7.
35. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142:4795-805.
36. Worthington J, Robson T, O'Keeffe M, Hirst DG. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: A novel suicide gene therapy. Gene Ther 2002; 9:263-9.
37. Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 2004; 6:673-80.
38. Scott SD, Joiner MC, Marples B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther 2002; 9:1396-402.
39. Greco O, Joiner MC, Doleh A, Scott SD. VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions. Gene Ther 2005.
40. Scott SD, Marples B, Hendry JH, Lashford LS, Embleton MJ, Hunter RD, Howell A, Margison GP. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther 2000; 7:1121-5.
41. McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, McKeown SR, Hirst DG, Robson T. p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 2007; 14:246-55.
42. Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, Mauceri HJ. Radiation-induced tumour necrosis factor-alpha expression: Clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 2002; 3:665-71.
43. Mezhir JJ, Smith KD, Posner MC, Senzer N, Yamini B, Kufe DW, Weichselbaum RR. Ionizing radiation: A genetic switch for cancer therapy. Cancer Gene Ther 2006; 13:1-6.
44. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002; 38:240-57.
45. Marignol L, Lawler M, Coffey M, Hollywood D. Achieving hypoxia-inducible gene expression in tumors. Cancer Biol Ther 2005; 4:359-64.
46. Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther 2002; 9:1403-11.
47. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996; 56:1834-41.
48. Chadderton N, Cowen RL, Sheppard FC, Robinson S, Greco O, Scott SD, Stratford IJ, Patterson AV, Williams KJ. Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. Int J Radiat Oncol Biol Phys 2005; 62:213-22.
49. Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer. Gene Ther 2006; 13:206-15.
50. Lipnik K, Greco O, Scott S, Knapp E, Mayrhofer E, Rosenfellner D, Gunzburg WH, Salmons B, Hohenadl C. Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. Virology 2006; 349:121-33.
51. Weichselbaum RR, Hallahan DE, Sukhatme VP, Kufe DW. Gene therapy targeted by ionizing radiation. Int J Radiat Oncol Biol Phys 1992; 24:565-7.
52. McLoughlin JM, McCarty TM, Cunningham C, Clark V, Senzer N, Nemunaitis J, Kuhn JA. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: Surgical experience and long-term follow-up. Ann Surg Oncol 2005; 12:825-30.
53. Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004; 10:5747-53.
54. Sonveaux P, Frerart F, Bouzin C, Brouet A, Dewever J, Jordan BF, Gallez B, Feron O. Irradiation promotes Akt-targeting therapeutic gene delivery to the tumor vasculature. Int J Radiat Oncol Biol Phys 2007; 67:1155-62.
55. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006; 66:1434-45.
56. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110:475-82.
57. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-6.
58. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6:553-63.
59. Rochlitz CF. Gene therapy of cancer. Drugs Today (Barc) 2000; 36:619-29.
60. Louie KA, Weiner LP, Du J, Kochounian HH, Fling SP, Wei W, McMillan M. Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis. Gene Ther 2005.
61. Gust TC, Zenke M. RNA transfer and its use in dendritic cell-based immunotherapy. Expert Opin Biol Ther 2005; 5:173-81.
62. He Y, Zhang J, Mi Z, Robbins P, Falo Jr LD. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005; 174:3808-17.
63. Jevremovic D, Gulati R, Hennig I, Diaz RM, Cole C, Kleppe L, Cosset FL, Simari RD, Vile RG. Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. Am J Physiol Heart Circ Physiol 2004; 287:H494-500.
64. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4:101-17.
65. Zhang M, Stevens G. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines. Melanoma Res 1998; 8:510-5.
66. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23:75-111.
67. Chung SM, Advani SJ, Bradley JD, Kataoka Y, Vashistha K, Yan SY, Markert JM, Gillespie GY, Whitley RJ, Roizman B, Weichselbaum RR. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther 2002; 9:75-80.
68. Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001; 3:451-6.
69. Lu W, Li S, An P, Yu B. Enhancement of ionizing radiation on liposome-mediated gene delivery in human rectal cancer HR-8348 cells. Zhonghua Wai Ke Za Zhi 2002; 40:604-5.
70. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045.
71. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002; 8:1765-80.
72. Jounaidi Y, Doloff JC, Waxman DJ. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets 2007; 7:285-301.
73. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z, Van Meir EG. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004; 10:8603-12.
74. Willers H, Held KD. Introduction to clinical radiation biology. Hematol Oncol Clin North Am 2006; 20:1-24.
75. Everts M, Curiel DT. Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther 2004; 4:337-46.
76. Sanz L, Qiao J, Vile RG, Alvarez-Vallina L. Antibody engineering, virus retargeting and cellular immunotherapy: One ring to rule them all? Curr Gene Ther 2005; 5:63-70.
77. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: From basic science to clinical application. J Pathol 2006; 208:299-318.
78. Torres-Roca JF. The role of external-beam radiation therapy in the treatment of clinically localized prostate cancer. Cancer Control 2006; 13:188-93.
79. Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA. Therapeutic advances in local-regional therapy for stage III nonsmall-cell lung cancer: Evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 2006; 8:195-202.
80. Hall EJ, Wuu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56:83-8.
81. Smith RP, Heron DE, Huq MS, Yue NJ. Modern radiation treatment planning and delivery - from Rontgen to real time. Hematol Oncol Clin North Am 2006; 20:45-62.
82. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen II. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62:1195-203.
83. Thames Jr HD, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8:219-26.
84. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M. Radiotherapy for high-grade gliomas: Does altered fractionation improve the outcome? Strahlenther Onkol 2004; 180:401-7.
85. Antognoni P, Corvo R, Zerini D, Orecchia R. Altered fractionation radiotherapy in head and neck cancer: Clinical issues and pitfalls of "evidence-based medicine". Tumori 2005; 91:30-9.
86. Ruggieri R. Hypofractionation in nonsmall cell lung cancer (NSCLC): Suggestions from modelling both acute and chronic hypoxia. Phys Med Biol 2004; 49:4811-23.
87. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002; 16:430-50.
88. Serganova I, Blasberg R. Reporter gene imaging: Potential impact on therapy. Nucl Med Biol 2005; 32:763-80.
89. Mocanu JD, Yip KW, Alajez NM, Shi W, Li JH, Lunt SJ, Moriyama EH, Wilson BC, Milosevic M, Lo KW, van Rooijen N, Busson P, Bastianutto C, Liu FF. Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther 2007; 15:921-9.
90. Raman V, Artemov D, Pathak AP, Winnard Jr PT, McNutt S, Yudina A, Bogdanov Jr A, Bhujwalla ZM. Characterizing vascular parameters in hypoxic regions: A combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res 2006; 66:9929-36.
91. Dasu A, Toma-Dasu I, Karlsson M. The effects of hypoxia on the theoretical modelling of tumour control probability. Acta Oncol 2005; 44:563-71.
92. Wang JZ, Li XA, Mayr NA. Dose escalation to combat hypoxia in prostate cancer: A radiobiological study on clinical data. Br J Radiol 2006; 79:905-11.
93. Sovik A, Malinen E, Bruland OS, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: A modelling study. Phys Med Biol 2007; 52:499-513.
94. Southgate TD, Sheard V, Milsom MD, Ward TH, Mairs RJ, Boyd M, Fairbairn LJ. Radioprotective gene therapy through retroviral expression of manganese superoxide dismutase. J Gene Med 2006; 8:557-65.
95. Greenberger JS, Epperly MW, Gretton J, Jefferson M, Nie S, Bernarding M, Kagan V, Guo HL. Radioprotective gene therapy. Curr Gene Ther 2003; 3:183-95.
96. Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol 2007; 25:924-30.
97. Khoo VS, Joon DL. New developments in MRI for target volume delineation in radiotherapy. Br J Radiol 2006; 79(Spec No 1):S2-15.
98. Jung M, Zhang Y, Dimtchev A, Subramanian MR, Suthanthiran K, Dritschilo A. Interstitial gene delivery in human xenograft prostate tumors using titanium metal seeds. Mol Cancer Ther 2004; 3:655-9.